AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30826774
Drug: ianalumab 10
RxNorm normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ianalumab 10 mg/kg
Trial: 26100253
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) combined with standard chemotherapy
Trial: 24094982
Drug: Perioperative low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative low dose vaginal oestrogens
Trial: 19847908
Drug: Rituximab (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1,000 mg intravenous infusions every 24 weeks for 96 weeks)
Trial: 3276283
Drug: mCPP administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mCPP administration after clomipramine treatment
Trial: 3276283
Drug: mCPP administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mCPP administration before clomipramine treatment
Trial: 30671976
Drug: Curcumin (1440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1440 mg/day) for 6 months
Trial: 21617168
Drug: A1AT replacement
RxNorm normalized name: Dcr-a1at
DrugBank: Belcesiran (DB18226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A1AT replacement therapy
Trial: 7503196
Drug: 2% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% clindamycin vaginal cream
Trial: 28615379
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS-PL) containing 250 μg I, 20 g/d, 118 kcal
Trial: 21810005
Drug: Olopatadine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine 5 mg twice daily (drug‐change group)
Trial: 21810005
Drug: Cetirizine 10
RxNorm normalized name: cetirizine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 10 mg once daily (initial treatment)
Trial: 21118744
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of venlafaxine extended-release 75-mg capsules (fasting)
Trial: 21118744
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of venlafaxine extended-release 75-mg capsules (fasting)
Trial: 21118744
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of venlafaxine extended-release 75-mg capsules (fed)
Trial: 21118744
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (fasting and fed)
Trial: 10410404
Drug: Isobaric tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isobaric tetracaine (2.0 mL of 0.5% tetracaine in cerebrospinal fluid)
Trial: 2188926
Drug: aclacinomycin-A (ACM-A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aclacinomycin-A (ACM-A, 100 mg/m2 or 85 mg/m2, every 3 weeks)
Trial: 23377392
Drug: Efinaconazole 10%
RxNorm normalized name: EFINACONAZOLE 10% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efinaconazole 10% solution (with or without semiocclusion)
Trial: 23377392
Drug: Efinaconazole 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efinaconazole 5% solution
Trial: 19534587
Drug: Sodium tanshinone
RxNorm normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium tanshinone IIA sulfonate (STS) 60 mg day(-1) injections for 13 days
Trial: 19534587
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections for 13 days
Trial: 15375791
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of adiponectin with insulin sensitivity
Trial: 24866597
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both methods
Trial: 9505987
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg venlafaxine tablet
Trial: 9505987
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg venlafaxine tablet with food
Trial: 9505987
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg venlafaxine solution
Trial: 2036242
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus radiotherapy (total nodal or involved field irradiation)
Trial: 30088663
Drug: ACT-246475 1
RxNorm normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-246475 1 mg
Trial: 30088663
Drug: ACT-246475 2
RxNorm normalized name: sodium fluoride 0.2 MG/ML [ACT Fluoride Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-246475 2 mg
Trial: 30088663
Drug: ACT-246475 4
RxNorm normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-246475 4 mg
Trial: 30088663
Drug: ACT-246475 8
RxNorm normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-246475 8 mg
Trial: 1833834
Drug: Isradipine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5.0 mg twice daily
Trial: 6126425
Drug: PCPL injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCPL injections
Trial: 17766093
Drug: Levetiracetam (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (1500 mg/day)
Trial: 9853771
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ursodeoxycholic acid and S-adenosylmethionine
Trial: 7893582
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg daily for 2 weeks)
Trial: 2735626
Drug: Zidovudine, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine, 250 mg orally every 4 hours
Trial: 2735626
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (including zidovudine and placebo)
Trial: 31788741
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy (VMP)
Trial: 28129949
Drug: SMS text
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS text message intervention (daily reminders to monitor RMC)
Trial: 26596540
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy for chest pain (CBT‐CP)
Trial: 11120521
Drug: Pregestational diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregestational diabetes mellitus requiring insulin therapy
Trial: 8317684
Drug: ketamine-racemat 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine-racemat 2 mg/kg
Trial: 3987645
Drug: Cimetidine 1200
RxNorm normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1200 mg/day
Trial: 3743626
Drug: Digoxin 0.75
RxNorm normalized name: digoxin 0.75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.75 mg i.v. with cimetidine
Trial: 31971474
Drug: Local heat
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local heat therapy (HT)
Trial: 10542928
Drug: Topical AMETOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical AMETOP gel
Trial: 10542928
Drug: Topical intranasal
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical intranasal cocaine (administered to all groups)
Trial: 2358837
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with cyclophosphamide 4.5 to 5.25 g/m2, etoposide 750 to 1,200 mg/m2, and cisplatin 120 to 180 mg/m2 (CVP)
Trial: 2358837
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with cyclophosphamide, etoposide, and cisplatin
Trial: 778990
Drug: Floctafenine 200
RxNorm normalized name: floctafenine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floctafenine 200 mg four times a day
Trial: 25923818
Drug: Ultrasound-guided unilateral
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided unilateral TAP block with 20 mL 7.5 mg/mL ropivacaine
Trial: 21586838
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (0.5 mg in 0.05 ml) monthly for 3 months
Trial: 21586838
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg in 0.05 ml) monthly for 3 months
Trial: 10731382
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily physical activity (Group 2, n = 64)
Trial: 9042560
Drug: Enoxaparin 40mg
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40mg once daily for 21 days
Trial: 9042560
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 21 days
Trial: 1331558
Drug: Droperidol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.25 mg.kg‐1 and fentanyl 5 micrograms.kg‐1 (group N)
Trial: 3901663
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen of acetylsalicylic acid
Trial: 3901663
Drug: 3-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose regimen of acetylsalicylic acid
Trial: 26727506
Drug: High-dose trans-resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose trans-resveratrol (450 mg/d)
Trial: 24183737
Drug: Preoperative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative dose of antibiotic (1g of amoxicillin) followed by a 3-day postoperative course.
Trial: 12971031
Drug: Levofloxacin administered
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin administered with juice and cereal without milk
Trial: 11039508
Drug: Ifosfamide (IFX)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide (IFX) 2,000 mg/m2 IV infusion days 1 to 3; 2-mercaptoethanesulfonic acid sodium salt (mesna) 400 mg/m2 IV bolus H 0 and 4, 800 mg/m2 by mouth H 8, days 1 to 3; Vinorelbine (VNB) 25 mg/m2 IV infusion days 1 and 8; Cisplatin (CDDP) 75 mg/m2 IV day 3, repeated every 28 days for a total of three courses
Trial: 30419961
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of conventional medicine and Traditional Chinese Medicine (TCM), administered twice daily for 28 days.
Trial: 30419961
Drug: Conventional medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medicine alone (control group).
Trial: 26880794
Drug: 0.1 mg/kg midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg midazolam
Trial: 26880794
Drug: 1 mg/kg ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg ketamine
Trial: 23019943
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy combined with Kanglaite Injection (KI) at 100 mL/d for 21 days, two cycles with one week interval.
Trial: 20430262
Drug: Inhaled treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled treprostinil (up to 54 mug) 4 times daily
Trial: 8652332
Drug: MgSO4 60
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 60 mg kg‐1 at recovery from vecuronium block to a TOF ratio of 0.7
Trial: 6354282
Drug: Prednisolone (200‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (200‐300 mg over 48‐72 h)
Trial: 18180279
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml triamcinolonacetonide (TCA)
Trial: 15483019
Drug: Remaining group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remaining group (not specified treatment)
Trial: 15483019
Drug: Cisplatin monotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin monotherapy (3 postoperative courses)
Trial: 26302900
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control group (treatment as usual for eight weeks)
Trial: 18081357
Drug: Torasemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (20 mg IV and 20 mg orally)
Trial: 18081357
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg IV and 80 mg orally)
Trial: 10480767
Drug: human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: human insulin 30/70
Trial: 11575978
Drug: Ximelagatran 8
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 8 mg twice daily
Trial: 11575978
Drug: Ximelagatran 12
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 12 mg twice daily
Trial: 11575978
Drug: Ximelagatran 18
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 18 mg twice daily
Trial: 2740834
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CH and Triton X‐100
Trial: 28754483
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg in two 150 mg tablets, twice daily)
Trial: 19641893
Drug: Prehospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital treatment and emergency management of pediatric trauma patients
Trial: 7825247
Drug: Multiple cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple cytotoxic drug regimens
Trial: 16648513
Drug: Adjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant systemic therapy
Trial: 21199608
Drug: Distributed constraint-induced
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distributed constraint-induced therapy (dCIT)
Trial: 1861872
Drug: Desipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (mean dose, 201 mg/day)
Trial: 31100237
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) in WW group
Trial: 25198030
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a 5 grass pollen mixture
Trial: 31272379
Drug: i-gel™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel™
Trial: 11823078
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg) + Heparin (5,000 IU 10 min before exercise, followed by 1,000 IU/h)
Trial: 11823078
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg) + Saline (10 ml 10 min before exercise)
Trial: 11823078
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Heparin (5,000 IU 10 min before exercise, followed by 1,000 IU/h)
Trial: 2188239
Drug: Permethrin 5%
RxNorm normalized name: PERMETHRIN 5% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 5% cream (Elimite)
Trial: 2188239
Drug: Crotamiton 10%
RxNorm normalized name: CROTAMITON 10% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crotamiton 10% cream (Eurax)
Trial: 22594116
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Group E)
Trial: 26227279
Drug: Reduced glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced glycerin vaginal formulation (RGVF)
Trial: 26227279
Drug: Isoosmolal rectal-specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoosmolal rectal-specific formulation (RF)
Trial: 25005333
Drug: Calcium-vitamin D
RxNorm normalized name: Calcium-Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin D co-supplementation (50,000 U/week vitamin D + 1,000 mg/day calcium)
Trial: 22390325
Drug: Eye patches
RxNorm normalized name: CAMPHOR, (-)- 1 g in 24 g TOPICAL PATCH [Eye Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye patches (four main brands)
Trial: 20533214
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (250 mg every other day for 12 weeks)
Trial: 15080373
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg daily) with or without indapamide (2 mg daily)
Trial: 2782470
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (hospital milieu therapy, pharmacotherapy, clinical management sessions)
Trial: 7034157
Drug: Endoscopic YAG-laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic YAG-laser treatment
Trial: 7034157
Drug: Endoscopic YAG-laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic YAG-laser treatment vs Control group
Trial: 24061999
Drug: Erythromycin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (0.25 g tid po for 1 week)
Trial: 3735482
Drug: NaHCO3 0.15
RxNorm normalized name: NaHCO3 0.15 MEQ/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 0.15 g per kg body weight
Trial: 3735482
Drug: NaHCO3 0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 0.30 g per kg body weight
Trial: 31427292
Drug: Piperacillin-tazobactam (TZP)
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (TZP) 75 mg/kg every 4 h infused over 0.5 h for infants ages 2 to <6 months
Trial: 31427292
Drug: Piperacillin-tazobactam (TZP)
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (TZP) 130 mg/kg every 8 h infused over 4 h for children ages >6 months to 6 years
Trial: 31324600
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events during treatment
Trial: 28725956
Drug: Child‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child‐ and Family‐Focused Cognitive‐Behavioral Therapy (CFF‐CBT)
Trial: 12416945
Drug: Cardioselective β-blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardioselective β-blocker (continued treatment) in patients with COPD
Trial: 10220232
Drug: Overall costs
RxNorm normalized name: costus root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall costs for all agents except chlorthalidone
Trial: 3328986
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen (40 mg daily for 2 years)
Trial: 7191298
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg oxprenolol twice a day
Trial: 7191298
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg slow-release oxprenolol once a day
Trial: 31227466
Drug: Ultrasound-guided single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided single-dose interscalene block (USG SDIB)
Trial: 28961662
Drug: Citalopram monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram monotherapy (DOCS group)
Trial: 23842022
Drug: Paliperidone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone (up to 9 mg/d)
Trial: 22544579
Drug: Bevacizumab maintenance
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab maintenance every 21 days after initial treatment with bevacizumab 15 mg/kg, pemetrexed 500 mg/m², and carboplatin AUC 6 every 21 days for 6 cycles.
Trial: 22544579
Drug: Treatment-related grade
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related grade 3/4 toxicities during initial treatment.
Trial: 25311306
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus PCV chemotherapy
Trial: 11696471
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy (group W)
Trial: 11696471
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy (subject A)
Trial: 22918094
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol